Manual lymphatic drainage for lymphedema following breast cancer treatment.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 25994425 · doi:10.1002/14651858.CD003475.pub2
What was done
A Cochrane systematic review and meta-analysis assessing the efficacy and safety of manual lymphatic drainage (MLD) for breast cancer-related lymphedema (BCRL). Databases (Medline, EMBASE, CENTRAL, WHO ICTRP, and Cochrane registers) were searched through May 2013 for randomized controlled trials (RCTs) or quasi-RCTs. Primary outcomes were volumetric changes (lymphedema volume, volume reduction, and percent reduction) and adverse events; secondary outcomes included function, subjective sensations (pain, heaviness), quality of life (QoL), and cost. Continuous data were pooled using fixed-effect models to calculate mean differences (MDs) with 95% confidence intervals (CIs).
What was found
Six trials were included, with individual sample sizes ranging from 24 to 45 participants: - MLD plus compression bandaging versus compression bandaging alone (2 RCTs, n = 83): Adding MLD resulted in a statistically significant additional percent volume reduction (MD 7.11%, 95% CI 1.75% to 12.47%). Absolute volume reduction was borderline significant (P = 0.06), while post-treatment lymphedema volume showed no significant difference. Subgroup analysis indicated greater benefit in mild-to-moderate BCRL compared to moderate-to-severe BCRL. - MLD plus standard physiotherapy versus standard physiotherapy alone (1 trial): Both groups improved from baseline, but between-group difference for percent reduction was not statistically significant. - MLD plus compression versus active non-MLD comparator plus compression (3 trials, clinically heterogeneous): In one trial (n = 24), MLD plus sleeve significantly improved volume reduction over pneumatic pump plus sleeve (MD 47.00 mL, 95% CI 15.25 to 78.75 mL), but percent reduction was borderline (P = 0.07). In a second trial (n = 31), MLD plus sleeve showed lower post-treatment excess volume versus simple lymphatic drainage (SLD) plus sleeve (MD -230.00 mL, 95% CI -450.84 to -9.16 mL), but no difference in volume reduction. In a third trial (n = 28), MLD plus bandaging was not significantly better than SLD plus bandaging (P = 0.10). - Safety and secondary outcomes: MLD was well-tolerated and safe across trials. Functional outcomes (range of motion, strength) and subjective sensations showed no consistent between-group differences. QoL data were missing or unusable, and costs were not reported.
Why it matters
MLD appears safe and may provide a modest additional reduction in arm swelling when combined with compression bandaging in mild-to-moderate BCRL, though it does not show clear evidence of improving function or patient-reported symptoms.
Limits
The evidence base is limited by small sample sizes (24 to 45 participants per trial) and few trials per comparison. In four of the six trials, outcome assessors measuring limb swelling were unblinded, introducing substantial risk of detection bias. Secondary clinical endpoints like range of motion, symptoms, and quality of life were inconsistently measured or inadequately reported.